Glycoprotein IIb/IIIa inhibitors use in the setting of primary percutaneous coronary intervention for ST elevation myocardial infarction in patients pre-treated with newer P2Y12 inhibitors,Clinical Cardiology

当前位置： X-MOL 学术 › Clin. Cardiol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Glycoprotein IIb/IIIa inhibitors use in the setting of primary percutaneous coronary intervention for ST elevation myocardial infarction in patients pre-treated with newer P2Y12 inhibitors
Clinical Cardiology ( IF 2.7 ) Pub Date : 2021-06-11 , DOI: 10.1002/clc.23654
Katrien Blanchart ₁ , Thibaut Heudel ₁ , Pierre Ardouin ₁ , Adrien Lemaitre ₁ , Clément Briet ₁ , Mathieu Bignon ₁ , Rémi Sabatier ₁ , Damien Legallois _{1,

2} , Vincent Roule _{1,

2} , Farzin Beygui _{1,

2}

Affiliation

We sought to investigate the safety and potential benefit of administrating glycoprotein IIb-IIIa inhibitors (GPIs) on top of more potent P2Y12 inhibitors.

中文翻译：